Pharmaceutical

Novartis snaps up rare disease biotech DTx Pharma in $1...

The acquisition adds an siRNA delivery platform to Novartis’s armament and a pot...

Pieris Pharma lays off 70% of workforce amid company re...

The biotech announced its employee cuts as part of a strategic update partly cau...

Amarin restructures to counter downturn following Vasce...

Amarin Corporation has initiated a company restructuring programme, following a ...

US DoD enlists VitriVax to develop one-shot vaccine for...

B. pseudomallei is resistant to many antibiotics and, without treatment, can be ...

Santhera and Catalyst to market DMD drug vamorolone in ...

The agreement covers licensing rights in North America for Duchenne muscular dys...

Novartis reports 7% rise in Q2 2023 net sales

Novartis has reported net sales of $13.62bn in Q2 of 2023, indicating a 7% rise ...

Advent receives US NIH grant for bronchopulmonary dyspl...

Advent Therapeutics has received a grant worth $3m from the US NIH for expeditin...

Telix adds another trial in its targeted radiation ther...

The Phase I trial evaluates the combination Telix’s targeted radiation therapy w...

Flagship Pioneering collaborates with Pfizer to develop...

Flagship Pioneering has entered into a collaboration with Pfizer to develop a ne...

STAT+: Bernie Sanders adds three drug shortage policies...

Sen. Bernie Sanders added three drug shortage measures to a pandemic-preparednes...

STAT+: At Orexo, a ‘turning point’ for everything but d...

Most everything is looking up for Orexo, the company reported on its earnings ca...

A new study shows how Medicaid coverage policies shape ...

Low-income immigrant mothers often lose insurance eligibility as soon as they gi...

STAT+: Johnson & Johnson sues to stop Medicare negotiation

Pharmaceutical giant Johnson & Johnson is the third drugmaker to sue the Biden a...

STAT+: ‘Doctors need to get on top of this’: GPT-4 disp...

“GPT-4, being trained off of our own textual communication, shows the same — or ...

STAT+: Novartis is scolded by U.K. trade group for the ...

For the third time this year, Novartis has been rebuked by a U.K. trade group fo...

STAT Virtual Event: The State of Biosimilars: What to W...

Join STAT for a discussion of what's next for biosimilars, and what key signals ...